Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

NCT06797869 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06797869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06797869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
January 29, 2025
Completion date
August 5, 2026
Enrollment
142 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, diabetic peripheral neuropathy